Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market and a regional leader in hospital ...

By CH Unnikrsihnan Drug maker and researcher Glenmark Pharmaceuticals Ltd's new biological drug candidate Bi-Specific ...

This week's report explores the pharmaceutical industry’s evolution toward resilient, scalable systems that prioritize ...

The launch follows a Delhi High Court nod allowing sales of the cancer drug biosimilar ahead of patent expiry in May 2026.

Zydus has launched Tishtha, an affordable biosimilar of nivolumab, at nearly one-fourth the original price. Approved by the ...

As cancer cases climb steadily across India, lower-cost biosimilars like Tishtha could reshape access to life-saving ...

This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...

At the end of last year, an Ebola disease outbreak in the Democratic Republic of Congo’s Kasai province was officially declared over.

Research efforts are ongoing to develop safer, broad-spectrum antivenoms. Technology Networks sat down with Dr. Andreas Laustsen-Kiel to learn more about a novel antivenom capable of protecting ...

Researchers in Switzerland have conducted the first systematic study that demonstrated that even small variations in a person’s genome can disrupt the therapeutic effects of monoclonal antibodies. “We ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.